Evolocumab reduces the incidence of first major adverse cardiovascular events by 25% in high-risk patients without prior myocardial infarction or stroke over a treatment duration of 4.6 years, with no increase in adverse events compared to control.

Study: Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes

This study found that a cholesterol-lowering drug called evolocumab helped people with diabetes but no prior heart attacks or strokes have fewer serious heart problems, without causing more side effects — just like the claim says.

Study: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.

This study found that a drug called evolocumab helped people at high risk for heart problems — who hadn't yet had a heart attack or stroke — have 25% fewer serious heart or blood vessel events over nearly five years, without causing more side effects.

Study: Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial.

This study found that a drug called evolocumab helped people at high risk for heart problems—those who’d had a stent but never had a heart attack or stroke—have fewer serious heart events over nearly five years, without causing more side effects. It worked even better than the 25% reduction claimed.